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Early Neural and Vascular Dysfunctions in Diabetic Rats
Are Largely Sequelae of Increased Sorbitol Oxidation
Yasuo Ido,1 Jens R. Nyengaard,2 Kathy Chang,3 Ronald G. Tilton,4 Charles Kilo,3
Banavara L. Mylari,5 Peter J. Oates,6 and Joseph R. Williamson7
Abstract
These experiments were undertaken to assess the importance of cytoplasmic (c) sorbitol oxidation versus mi-
tochondrial (m) pyruvate oxidation in mediating neural and vascular dysfunction attributable to hyperglycemia
in diabetic rats. Increased oxidation of sorbitol is coupled to enzymatic reduction of free oxidized NADþc to
reduced NADHc, manifested by an increased ratio of NADH to NADþc. Likewise, increased oxidation of
pyruvate is coupled to reduction of NADþm to NADHm, which increases the NADH=NADþm ratio. Specific
inhibitors of sorbitol production or sorbitol oxidation normalized: increased diabetic nerve NADH=NADþc,
impaired nerve-conduction velocity, and vascular dysfunction in sciatic nerve, retina, and aorta; however, they
had little or no impact on increased NADH=NADþm. These observations provide, for the first time, strong in vivo
evidence for the primacy of sorbitol oxidation versus. pyruvate oxidation in mediating the metabolic imbalances,
impaired nerve conduction, and vascular dysfunction evoked by diabetes. These findings are consistent with (a)
the fact that oxidation of sorbitol produces ‘‘prooxidant’’ NADHc uncoupled from subsequent production of
‘‘antioxidant’’ pyruvate required for reoxidation of NADHc to NADþc by lactate dehydrogenase, and (b) the
hypothesis that neural and vascular dysfunction in early diabetes are caused primarily by increased NADHc,
which fuels superoxide production by NADH-driven oxidases. Antioxid. Redox Signal. 12, 39–51.
Introduction
Increasing evidence supports the importance of superox-ide (O2) and related reactive oxygen species (ROS) in
mediating diabetic complications attributed to hyperglycemia
(4, 5, 8, 20, 29, 52); however, the primary source(s) of electrons
that fuel superoxide production is controversial. Two dis-
tinctly different hypotheses have been proposed: (a) increased
oxidation of pyruvate (produced by increased glycolysis) in
mitochondria coupled to reduction of free NADþm to
NADHm, which promotes superoxide production by the
mitochondrial electron transport chain (5, 29); and (b) in-
creased oxidation of sorbitol (produced by increased flux of
glucose via the sorbitol pathway, which does not produce
pyruvate) by sorbitol dehydrogenase (SDH) to fructose cou-
pled to reduction of cytosolic NADþc to NADHc (equimolar
to fructose) that drives superoxide production primarily by
NADH-driven oxidases (20, 30, 55):
SorbitolþNADþ c !SDH fructoseþNADHcþHþ ;
NADHcþO2 !NADH oxidases NADþ cþO2 
The first hypothesis suggests that pyruvate supplementa-
tion might mimic or exacerbate metabolic imbalances and
vascular and neural dysfunction evoked by hyperglyce-
mia. However, pyruvate supplementation (a) normalizes=
attenuates vascular dysfunction and metabolic imbalances
evoked by hyperglycemia in several different paradigms of
diabetes (16, 24, 44, 48, 50, 57), and (b) attenuates cataract
formation in diabetic rats (58).
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The second hypothesis suggests that sorbitol supplemen-
tation (at normal glucose levels) might cause oxidative stress
and associated metabolic imbalances and vascular dysfunc-
tion comparable to hyperglycemia=diabetes. This prediction
has been confirmed in many investigations in tissues and cells
exposed to elevated sorbitol levels in vivo and in vitro [9, 12,
26, 30 (pages 9–10 inOnline Appendix Section (OAS)-IV-A see
Supplemental Appendix at www.liebertonline.com=ars), 46,
47, 49, 53}. These effects of sorbitol also are prevented
or substantially attenuated by coadministration of pyruvate,
SOD (superoxide dismutase), and/or by inhibitors of SDH
(SDI), or both (12, 26, 46, 47, 53). These effects of pyruvate and
sorbitol are consistent with a potentially important role for
sorbitol oxidation in mediating oxidative stress and vascular
and neural dysfunction evoked by diabetes.
Observations that SDI and SOD prevent sorbitol-induced
vascular dysfunction and superoxide production are consis-
tent with numerous observations in animal models of diabe-
tes that inhibition of sorbitol production by aldose reductase
(AR) inhibitors (ARI) also prevent=attenuate vascular and
neural dysfunction, oxidative–nitrosative stress, and the pre-
dicted increases in free NADH=NADþc (6, 10, 20, 30–37, 39,
48, 50, 55, and OAS I-D, I-E).
To the extent that metabolic imbalances and vascular and
neural changes in early diabetes are largely sequelae of in-
creased sorbitol oxidation rather than oxidation of NADPHc
to NADPþc by AR, they should be prevented by ARI or SDI:
GlucoseþNADPHcþHþ !ARI jj sorbitolþNADPþ c
SorbitolþNADþ c !SDIH jj fructoseþNADHcþHþ
However, Cameron et al. (6) reported that ARI-WAY-
121,509, but not SDI-WAY-135,706, reversed impaired nerve
conduction and sciatic nerve blood flow, and Obrosova et al.
(34, 36) reported that SDI-157 failed to attenuate increases in
retinal and sciatic nerve NADH=NADþc or NADH=NADþm
in diabetic rats.
The current studies were therefore undertaken to clarify
and further to investigate the (a) contributions of increases in
NADH=NADþc versus. NADH=NADþm in mediating neural
and vascular dysfunction evoked by diabetes, and (b) effi-
cacy of SDI versus. ARI in preventing and reversing sorbitol
pathway–linked increases in NADH=NADþc and associated
neural and vascular dysfunction.
Materials and Methods
Animal protocols
Male Sprague–Dawley rats were purchased from Sasco
(O’Fallon, MO) and cared for in accordance with guidelines of
the University Committee for the Humane Care of Laboratory
Animals. Rats were housed one per cage and had free access
to standard rat chow (Ralston Purina, Richmond, IN) and tap
water. Diabetes was induced after an overnight fast by in-
jection of 50mg=kg body weight (bwt) of streptozotocin
(Zanosar obtained from Upjohn) in citrate saline buffer, pH
4.5. Rats were anesthetized with ketamine (Vetalar, 35mg=kg
bwt), and streptozotocin was injected in a surgically exposed
femoral vein. Nonfasting blood samples were obtained
3–4 days later from a tail vein for measurement of plasma
glucose levels with the hexokinase method, as in previous
experiments (39). Rats with plasma glucose levels of 16.7mM
(300mg=dl) or more were considered to be diabetic and were
distributed to groups of untreated, and ARI- and SDI-treated
diabetics balanced to achieve mean SD values of glucose
levels that did not differ ( p> 0.05) among the groups. SDI and
ARI treatments were then initiated. Plasma glucose levels and
HbA1c levels were assessed again after 2 and 4 weeks of
treatment in all studies, and then at 4-week intervals, de-
pending on the duration of diabetes, and again at the termi-
nation of each study. Plasma glucose levels shown in the
Results sections and in tables are expressed as mean SD of
glucose levels measured at intervals of 2–4 weeks and at the
termination of the study.
Because neural and vascular dysfunction varies with du-
ration and severity of diabetes, prevention studies were first
performed in rats with diabetes of 5 and 18 weeks duration.
Subsequently, the efficacy of SDI and ARI in reversing neural
changes was assessed after 2 and 4 weeks of treatment initi-
ated after 6 weeks of untreated diabetes. Because our obser-
vation in this study (Reversal Study 1) that MNCV deficits
were normalized by the SDI were discordant with the failure
of an SDI to reverse MNCV deficits evoked by diabetes in the
report by Cameron et al. (6), this experiment was repeated
(Reversal Study 2) to validate the reproducibility of this ob-
servation and, in addition, to assess the relation of normali-
zation of MNCV deficits to changes in neural blood flow and
vascular leakage and changes in sorbitol, fructose, and myo-
inositol levels that were not assessed in Reversal Study 1.
SDI (CP-166,572 (i.e., SDI-158) (13) and two structurally
distinct ARIs, zopolrestat (28) and sorbinil (38), were synthe-
sized at Pfizer Global Research and Development, Groton, CT.
SDI was added to drinking water to provide a dose of
200mg=kg bwt=day; zopolrestat was added to chow to pro-
vide 50mg=kg bwt=day in the 5-week study and 100mg=kg
bwt=day in both reversal studies; sorbinil was added to
chow to provide 50mg=kg bwt=day in the 18-week study. Two
structurally different ARIs were used to minimize the possi-
bility that efficacy was an off-target effect. Dosages were based
on dose–response effects of the SDI and ARIs (33). Body
weightsweremonitoredweekly, and consumption of drinking
water and chow was checked every 2–3 days; quantities of
inhibitors were adjusted to provide the appropriate dosage.
Motor-nerve conduction
Motor-nerve conduction velocity (MNCV) was measured
in rats anesthetized with intramuscular injections of ketamine
(100mg=kg body wt). Core body temperature was main-
tained at 37 58C with the use of heating pads and lamps
controlled by a rectal temperature probe. Nerves were stim-
ulated with a Grass stimulator (model SDP; Quincy, MA) by
generating a rectangular pulse 0.2ms in duration at a voltage
sufficient to give a maximal response. The compound muscle
action potential was amplified and recorded on a digital-
storage oscilloscope 1425 (Gould, Oxnard, CA).
MNCV in the distal tibial branch of the sciatic nerve was
quantified by insertion of stimulating electrodes through the
skin at the popliteal fossa and the ankle to stimulate the nerve
and insertion of a concentric bipolar recording electrode into
the plantar muscle. MNCV was calculated by dividing the
distance between the two stimulating electrodes by the la-
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tency difference in the onset of the electromyographic (EMG)
potentials in the recording electrodes evoked by the two
stimulating electrodes. MNCV in the distal peroneal branch of
the sciatic nerve was quantified by inserting stimulating
electrodes at the sciatic notch and at the popliteal fossa to
stimulate the nerve and by insertion of the concentric bipolar
recoding electrode into the anterior tibial muscle. MNCVwas
calculated as described for the tibial nerve. MNCVs are re-
ported in meters per second (m=s).
Blood flow and vascular permeability measurements
One week after the last assessment of MNCV, sciatic nerve
and retinal blood flows and vascular albumin permeation
(VAP) were assessed, as previously described (39, 40), and
reported as microliters per gram (ml=g) wet wt=min and mg
plasma=g wet wt=min, respectively. Rats were anesthetized
with thiobutabarbital (Inactin), rather than ketamine, because
it has a longer duration of action needed for preparation and
assessment of blood flow and VAP. Blood flow was assessed
by injection of 11.3mm 46Sc-labeled microspheres. VAP was
quantified by the injection of [125I]-bovine serum albumin
followed by [131I]-albumin. Mean arterial blood pressure
(MABP) was monitored by inserting a polyethylene cannula
filled with heparinized saline (connected to a pressure trans-
ducer) into the right subclavian artery (10).
Metabolite measurements
One week after the final assessment of MNCV, rats were
again anesthetized with thiobutabarbital, and the portion of
sciatic nerve between the sciatic notch and the popliteal fossa
was rapidly removed, plunged into liquid nitrogen, and kept
at 808C before measurement of metabolites. Nerve polyols,
lactate and pyruvate levels, plasma glucose levels, and HbA1c
were quantified as described previously (30, 39, 45, 50).
Plasma b-hydroxybutyrate was determinedwith the standard
fluorescence enzymatic method in PCA-deproteinized sam-
ples (3). Plasma NEFA levels were assessed by using the
WAKO NEFA-C test kit (Wako Chemicals, Richmond, WA).
The ratio of sciatic nerve molar concentrations of free cy-
tosolic NADHc and free NADþc was estimated by the redox
metabolite indicator method (54). This method is based on the
near-equilibrium between the NADþ=NADHc ratio and the
ratio of the molar concentrations of lactate and pyruvate es-
tablished by lactate dehydrogenase (LDH), as depicted in Eqs.
1 and 2. The value of the unitless equilibrium constant KLDH is
1.111104 (at pH 7.0) (54):
NADþ cþ lactateÐLDH NADHcþpyruvate (Eq: 1):
NADH=NADþ c¼ (lactate=pyruvate) ·KLDH (Eq: 2):
Sciatic nerve molar ratios of free NADPH=NADPþc and
mitochondrial NADH=NADþm were assessed based on the
near-equilibria established between (a) NADPH=NADPþc
and malate=pyruvate ratios by the malic enzyme (19), and (b)
NADH=NADþm and b-hydroxybutyrate=acetoacetate ratios
by b-hydroxybutyrate-DH (54).
Statistical analysis
All results are reported as mean SD. Multiple analysis of
variance was performed on Blom-transformed data with the
SAS general linear models procedure; overall differences
among experimental groups for each parameter were first
assessed by the Van der Waerden test, and individual pair-
wise group comparisons were evaluated with least-square
means, as previously described (45).
Results
5 weeks of diabetes
Diabetes increased sciatic nerve endoneurial blood flow by
57%, VAP, 83%, andNADH=NADþc,*80% (Table 1). Retinal
blood flow and VAP were increased 14% and 83%, respec-
tively, and aortic VAP was increased 90% (from 98 16 mg
plasma=g wet wt=min in controls to 191 52; p< 0.001). SDI
and ARI prevented all of these changes.
Diabetes increased sciatic nerve sorbitol and fructose levels
by 12-fold and sevenfold, respectively, but decreased myo-
inositol levels 30%. The SDI increased sorbitol levels another
5.4-fold, whereas the ARI normalized them; nevertheless,
both inhibitors decreased fructose levels*80%.
Nerve sorbitol levels in SDI-treated controls equaled those
in untreated diabetic subjects, whereas in ARI-treated con-
trols, sorbitol levels were decreased to 22% of controls; fruc-
tose levels in SDI- and ARI-treated controls were significantly
decreased versus controls; blood flow, VAP, and myoinositol
levels in SDI- and ARI-treated controls did not differ from
controls.
Plasma glucose levels in untreated diabetic rats were
25.7 2.7mM vs. 6.2 0.7 in controls ( p< 0.001); glucose
levels in SDI- and ARI-treated diabetics were 26.0 4.0 and
27.0 3.6mM, respectively, and p< 0.001 vs. controls for both
groups. HbA1c levels were 11.1 2.0% in untreated diabetics
vs. 3.7 1.3% in controls ( p< 0.001); HbA1c levels in SDI- and
ARI-treated diabetics were 10.6 1.4% and 10.8 1.1%, re-
spectively; p< 0.001 vs. controls. Plasma glucose and HbA1c
levels in SDI- and ARI-treated diabetics did not differ
( p> 0.05) from those in untreated diabetics.
Mean arterial blood pressure (MABP) was 128 9mm Hg
in diabetics vs. 144 14 in controls ( p< 0.01). Initial body
weights were 240 12 g in diabetics vs. 259 17 in controls
( p< 0.02). Body weights increased 9.0 14% in diabetics vs.
33 11% in controls ( p< 0.001). MABP and body weights in
SDI- and ARI-treated diabetics did not differ from those in
untreated diabetics ( p> 0.05).
18 weeks of diabetes
Diabetes decreased MNCV 11.5% in the distal tibial nerve
(Fig. 1) and 10.4% in the peroneal nerve (from 65.3 4.2m=s
to 58.5 5.1; p< 0.01). Both inhibitors prevented theseMNCV
deficits. Diabetes increased sciatic nerve NADH=NADþc and
NADH=NADþm by 80% and 60%, respectively (Fig. 1); both
inhibitors prevented the increase in NADH=NADþc, but not
the increase in NADH=NADþm.
Diabetes also increased sciatic nerve NADPH=NADPþc
ratios *80%, which also were normalized by the SDI (Table
2). The ARI partially attenuated the increase in NADPH=
NADPþc (which did not differ significantly from controls or
diabetics) but did not affect malate=pyruvate ratios.
Plasma glucose levels in diabetic rats were increased
*sixfold (39.7 3.6mM vs. 6.9 0.5 in controls; p 0.001);
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HbA1c levels were increased by *3.3-fold (14.7 0.6% vs.
4.5 0.2% in controls; p 0.001). Plasma glucose and HbA1c
levels in ARI- and SDI-treated diabetic rats did not differ from
those in untreated diabetics (Table 2).
Nerve sorbitol and fructose levels were increased by dia-
betes by 13.4- and 5.7-fold, respectively (Table 2). The SDI
increased sorbitol levels another 3.9-fold and normalized
fructose levels. TheARI reduced sorbitol and fructose levels to
levels lower than those in controls ( p< 0.01). Myoinositol
levels were decreased *37% by diabetes and were normal-
ized by the ARI but unaffected by the SDI ( p< 0.0001 vs. SDI-
treated diabetics).
Plasma levels of NEFA were 69 17 mEq=dl in diabetics
versus 42 8 in controls ( p< 0.004); plasma b-HBA levels
were 102 51mM in diabetics vs. 27 3 in controls ( p< 0.001).
Neither the SDI nor the ARI significantly attenuated NEFA or
b-HBA levels in diabetics. Initial bodyweights were similar in
controls and diabetics; however, diabetics gained signifi-
cantly less weight than did controls ( p< 0.05).
Reversal of MNCV deficits and NADH=NADþc
by SDI and ARI
Reversal Study 1. After 6 weeks of untreated diabetes,
the MNCV was decreased *13–14% in all three groups of
diabetic rats (Fig. 2, left panel). After 8 weeks of untreated
diabetes, MNCV was decreased 17% (Fig. 2, middle panel).
SDI and ARI administered during the last 2 weeks attenuated
(but did not normalize) MNCV deficits to 11% and 4.6%, re-
spectively. After 10 weeks of untreated diabetes, MNCV was
decreased 14% and was statistically normalized by SDI and
by ARI administered during the last 4 weeks (Fig. 2, right
panel).
Diabetes increased sciatic nerve NADH=NADþc and
NADH=NADþm about twofold (Table 3). The ARI normal-
Table 1. 5 Weeks of Diabetes: Effects of the SDI and the ARI (Zopolrestat) on Blood Flow
and Vascular Albumin Permeation in Sciatic Nerve Endoneurium and Retina
and on Sciatic Nerve NADH=NADþc, Sorbitol, Fructose, and Myoinositol Levels
Sciatic nerve Retina
NADH=
Blood flow VAP NADþc Sorbitol Fructose Myoinositol Blood flow VAP
Control 65 16 76 13 1.1 0.4 159 55 814 197 4,148 1692 374 15 75 12
þSDI 64 17 75 13 – 2,050 697* 524 201* 4,351 1290 360 20 71 8
þARI 68 30 76 18 – 24 11* 179 60* 4,283 938 376 16 74 19
Diabetic 102 17* 139 16* 1.9 0.4{ 1,863 623* 5,815 1,711* 2,875 737§ 426 21* 137 16*
þSDI 67 26ll 89 25ll 1.3 0.4# 9,975 4397*ll 1,001 519ll 2,844 793§ 380 45ll 85 24ll
þARI 75 24# 94 3ll 1.2 0.4# 170 85ll 1,217 253{ll 3,521 1,229 382 33ll 91 38ll
BF, blood flow; VAP, vascular albumin permeation. Data are expressed as mean SD for 10–12 animals. Blood flow is expressed as ml=g
wet wt=min; vascular albumin permeation is expressed as mg plasma=g wet wt=min; sorbitol, fructose, and myoinositol levels are expressed
as nmol=g wet wt; see Research Design and Methods for calculation of free NADH=NADþc 103.
Different from Controls: *p 0.001, {p 0.005, §p< 0.04.
Different from Diabetics: llp 0.001, #p 0.01.
FIG. 1. Eighteen weeks of diabetes. Effects of SDI (200mg=kg bwt=day) and ARI (sorbinil, 50mg=kg bwt=day) on distal
tibial MNCV and on sciatic nerve NADH=NADþc and NADH=NADþm in rats with diabetes of 18 weeks’ duration.
Mean SD: n¼Nine to 12 rats for all parameters. Different from controls: *p< 0.001, {p¼ 0.005, {p< 0.02. Different from
diabetics: §p< 0.02, lIp¼ 0.05.
42 IDO ET AL.
ized the NADH=NADþc, but not the NADH=NADþm. The
SDI failed to normalize NADH=NADþc or NADH=NADþm.
(Failure of the SDI to normalize NADH=NADþc is consistent
with the substantially larger variance in NADH=NADþc than
in diabetics and ARI-treated diabetics and the unfavorable
pharmacokinetics of SDI, as discussed earlier (31, 33, 45).
Diabetes increased plasma glucose levels *4.4-fold
(35.1 4.7mM vs. 8.0 1.8, p 0.001) and increased HbA1c
levels 3.8-fold (14.1 1.0% vs. 3.7 0.4%; p 0.001). Plasma
glucose levels and HbA1c levels in diabetic rats treated with
SDI and ARI did not differ from those in untreated diabetics
(Table 3).
Diabetes increased NEFA and b-HBA levels by about two-
and fourfold; p 0.001). All three groups of diabetics failed to
gain weight in contrast to controls. These parameters were
unaffected by the SDI or ARI.
Reversal Study 2. After 6 weeks of untreated diabetes,
MNCV deficits ranged from 9.3 and 14.3% before adminis-
tration of SDI and ARI (Table 4). After 8 weeks of untreated
diabetes, theMNCVdeficit was 10.7% andwas not attenuated
by SDI or ARI treatment during the last 2 weeks. After
10 weeks of untreated diabetes, the MNCV deficit was 10.4%
and was normalized by SDI and by ARI administered during
the last 4weeks. Fourweeks of ARI treatment also normalized
the associated 19% reduction in nerve blood flow; however,
blood flow in SDI-treated diabetics was not significantly dif-
ferent from that in controls or untreated diabetics. Neither
inhibitor attenuated the associated 2.5-fold increase in VAP.
MABPwas 132 18mmHg in diabetics versus 148 5mmHg
in controls ( p< 0.01) and was unaffected by the SDI or ARI.
Diabetes increased sciatic nerve sorbitol and fructose levels
by 12-fold and sevenfold, respectively (Table 4). The SDI in-
creased sorbitol levels an additional fivefold (61 controls)
while normalizing fructose levels. The ARI decreased sorbitol
and fructose levels to 36 and 76%, respectively, of controls;
and fructose levels were 35% lower than those in SDI diabetics
( p< 0.02). Myoinositol levels were decreased 57% by diabetes
andwere unaffected by the SDI; however, the ARI normalized
myoinositol levels, which were 1.7-fold higher than those in
untreated diabetics ( p< 0.01) and*1.9-fold higher than those
in SDI diabetics ( p< 0.001).
Diabetes increased plasma glucose levels 4.5-fold (36.2mM
3.8 vs. 8.0 1.0 in controls; p 0.001); plasma glucose levels in
SDI- and ARI-treated diabetics were 34.4 3.5 and 35.0
3.7mM, respectively ( p 0.001 vs. controls) and did not differ
from those in untreated diabetics ( p> 0.05).
Diabetes also increased HbA1c levels by 3.9-fold
(14.0 1.4% vs. 3.6 0.2% in controls; p 0.001); HbA1c levels
in SDI- and ARI-treated diabetics were 13.4 1.6% and
13.4 1.1%, respectively ( p 0.001 vs. controls) and did not
differ from those in untreated diabetics ( p> 0.05).
Table 2. 18 Weeks of Diabetes: Effects of Diabetes, SDI, and the ARI-sorbinil on Sciatic Nerve
NADPH=NADPþ, Sorbitol, Fructose, and Myoinositol Levels in the Same Animals
in Which NADH=NADþc and NADH=NADþm are Shown in Fig. 1
Sciatic nerve
NADPH= Sorbitol Fructose Myoinositol PG HbA1c BWI BWC
NADPþ (nmol=g) (nmol=g) (nmol=g) (mM) (%) (g) (%)
Control 72 37 216 73 1,198 301 3,078 615 6.9 0.5 4.5 0.2 218 8 þ132 14
Diabetic 128 58{ 2,901 649{ 6,885 1,791* 1,941 246* 39.7 3.6* 14.7 0.6* 219 4 þ64 11*
þSDI 81 35* 11,241 3,630*§ 1,514 755§ 1,793 287* 35.6 1.3* 13.9 0.6* 221 6 þ56 14*
þARI 102 58 43 20*§# 899 170{§} 2,846 673lI# 36.1 4.4* 13.8 1.2* 224 8 þ54 18*
Final plasma levels of glucose (PG), HbA1c, initial body weights (BWI), and body-weight change (BWC).
Data are expressed as mean SD for seven to 11 animals.
Different from Controls: *p 0.001, {p< 0.003, {p< 0.01.
Different from Diabetics: §p< 0.0001, lIp 0.015, *p¼ 0.037.
Different from SDI-treated diabetics: #p¼ 0.0001, }p< 0.003.
FIG. 2. Reversal Study 1. Time course of re-
versal of impaired distal tibial MNCV by treat-
ment with an SDI (200mg=kg bwt=day) vs. an
ARI (zopolrestat, 100mg=kg bwt=day) initi-
ated after 6 weeks of untreated diabetes. Mean
SD; n¼ 9–10 rats for all parameters. Different
from controls: *p< 0.001, {p< 0.05. Different from
diabetics: {p< 0.001, §p< 0.04. Different from
diabeticsþ SDI: lIp¼ 0.013.
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Diabetes tended to increase NEFA (58 21mEq=dl vs. 42
14mEq=dl in controls); however, the difference was not signifi-
cant ( p> 0.05). NEFA levels in SDI- and ARI-treated diabetics
were slightly higher than those in untreated diabetics (71 39
and 77 26mEq=dl, respectively; p< 0.01 vs. controls for both
groups) but did not differ from those in untreated diabetics
( p> 0.05). Diabetes increased b-HBA levels by *5.4-fold to
113 84mM vs. 21 4 in controls ( p< 0.001); b-HBA levels in
SDI- and ARI-treated diabetics were 71 39 and 77 26, re-
spectively ( p 0.01 vs. controls and p> 0.05 vs. untreated dia-
betics). Initial body weights were 417 11g in controls and
diabetics; final body weights increased 35 7% in controls vs. a
weight loss of 9 9% in untreated diabetics (p< 0.001).
Weight losses in SDI- and ARI-treated diabetics were 6 4%
and 6 10%, respectively ( p> 0.05 vs. untreated diabetics).
Effects of diabetes, SDI, and ARI on sciatic nerve:
(a) malate levels and malate=pyruvate ratios
and (b) lactate=pyruvate ratios manifested
by changes in lactate and=or pyruvate levels Table 5
Effects of untreated diabetes. Lactate=pyruvate ratios
were increased by 1.5- to twofold in all three studies and were
attributable largely to increased lactate levels, except in the
18-week study in which lactate levels were identical to con-
trols, whereas pyruvate levels were decreased 43% (Table 5).
In the 10-week study, the increased lactate=pyruvate ratio
also was contributed to by a 19% decrease in pyruvate levels
that approached statistical significance ( p¼ 0.05–0.1). Malate
levels did not differ from controls, whereas malate=pyruvate
ratios were increased*80% ( p< 0.001 vs. controls).
Effects of SDI treatment. The SDI normalized lactate=
pyruvate ratios in the 5- and 18-week studies, but not in the
10-week reversal study. In the 5-week study, 87% normali-
zation of lactate=pyruvate ratios was due largely to increased
(33%) pyruvate levels, together with decreased (8%) lactate
levels. In the 18-week study, 83% normalization was due
entirely to increased pyruvate levels (77%). Malate levels did
not differ from those in controls or diabetics, whereas
malate=pyruvate ratios were normalized.
Effects of ARI treatment. The ARI normalized lactate=
pyruvate ratios in all three studies. In the 5-week study,
normalization was manifested by the combination of a mar-
ginally significant increase in pyruvate levels (28%; p¼ 0.05–
0.01) and a 17% ( p¼ 0.26) reduction in mean lactate levels. In
the 10-week study, normalization was due to significantly
increased pyruvate levels. In the 18-week study, normaliza-
tion was due to significantly increased pyruvate levels and a
statistically insignificant reduction in lactate levels. Malate
levels and malate=pyruvate ratios were not significantly dif-
ferent from those in the other groups.
Table 3. Reversal Study 1
NADH= NADH=
NADþc NADþm PG HbA1c NEFA b-HBA BWI BWC
Controls 1.4 0.5 32 14 8.0 1.8 3.7 0.4 40 12 27 6 382 7 þ48 8
Diabetics 2.9 0.9{ 64 19{ 35.1 4.7* 14.1 1.0* 73 24{ 107 99* 380 8  17 14*
þSDI 2.5 1.4§ 49 30 36.6 9.4* 13.5 0.9* 65 26lI 130 103* 397 18 þ0.9 0.9*
þARI 1.8 0.7# 48 18lI 33.4 11.9* 13.0 0.9* 75 31{ 99 57* 377 12 þ3.8 10*
Sciatic nerve NADH=NADþc and NADH=NADþm, HbA1c, and plasma glucose (PG), nonesterified fatty acids (NEFA), and b-
hydroxybutyrate (b-HBA) levels, initial body weights (BWIs) and body-weight change (BWC) for rats in which MNCV data are depicted in
Fig. 2.
Data are expressed as mean SD for seven to 10 animals. NADH=NADþc and NADH=NADþm are calculated as described in the Research
Design and Methods section and expressed as NADH=NADþc103 and NADH=NADþm103; plasma glucose levels are expressed as
mM; HbA1c, as a percentage of total Hb; NEFA, as mEq=dl; b-HBA as (mM); BWI in grams; and BWC as a percentage change from BWI.
Different from Controls: *p 0.001, {p< 0.002, {p< 0.01, §p< 0.02, lIp< 0.04.
Different from Diabetics: #p¼ 0.013.
Table 4. Reversal Study 2: Time Course of Reversal of Distal Tibial MNCV Deficits after 2 and 4 Weeks
of Treatment with the SDI or the ARI (Zopolrestat) Initiated after 6 Weeks of Untreated Diabetes (No Rx)
MNCV
6wk 8wk 10wk
(No Rx) (2wk Rx) (4wk Rx) BF VAP Sorbitol Fructose Myoinositol
Control 58.0 5.7 59.9 4.5 58.9 3.3 72 10 76 12 238 43 1,000 177 5,953 2,125
Diabetic 49.7 2.4* 53.5 4.1{ 52.8 3.2* 58 12{ 190 36* 2,811 692* 7,229 884* 2,573 425*
þSDI 52.6 3.7{ 52.8 3.9* 57.6 1.5lI 62 12# 213 48* 14,442 2,290*§ 1,163 435§} 2,292 535*^
þARI 51.8 5.0{ 55.0 4.1{ 57.4 3.3lI 78 15lI 178 41* 85 16*§ 758 148{§ 4,284 1,379lI
Also shown are sciatic nerve endoneurial blood flow (BF) and VAP (mg plasma=g=min) and sciatic nerve sorbitol, fructose, and myoinositol
levels after 4 weeks of treatment. Data are expressed as mean SD for nine to 10 animals.
Different from Controls: *p 0.001, {p 0.005, {p 0.034.
Different from Diabetics: §p 0.001, lIp 0.01.
Different from ARI-Rx Diabetics: ^p< 0.001, #p< 0.01, }p< 0.02.
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Discussion
The observations in these experiments support two fun-
damental conclusions and concepts: (a) increased sorbitol
oxidation plays a critical role in mediating diabetes-induced
early neural and vascular dysfunction that precede pathologic
structural changes, and (b) neural and vascular dysfunction
evoked by sorbitol oxidation are primarily sequelae of in-
creased cytoplasmic NADH=NADþc rather than elevated
mitochondrial NADH=NADþm. Notably, these are the first
studies in which neural or vascular dysfunction or both,
NADH=NADþc or NADH=NADþm or both have been
assessed in the same animal. Previous investigators have as-
sessed neural and vascular dysfunction but not NADH=
NADþc or NADH=NADþm (6), or NADH=NADþc and
NADH=NADþm, but not neural or vascular dysfunction (34).
The first conclusion is supported by the comparable effi-
cacy of SDI and ARI in preventing and reversing MNCV
deficits (Figs. 1 and 2, Table 4) and in preventing vascular
dysfunction in sciatic nerve, retina, and aorta in rats with
diabetes of 5 weeks’ duration (Table 1).
In two independent studies, the SDI and the ARI reversed
MNCV deficits (Fig. 2, Table 4) after 4 (but not 2) weeks of
treatment, after 6weeks of untreated diabetes.We confirm the
previous observation of Cameron et al. (6) that SDI treatment
for 2 weeks failed to reverse preexisting MNCV deficits. We
observed in addition, however, that SDI treatment for 4weeks
was as efficacious as ARI in reversing MNCV deficits (Fig. 2).
The biochemical explanation for clear SDI efficacy after 4 (but
not after 2) weeks of treatment is unclear and will require
future studies. The same SDI (albeit named differently) was
used by Cameron et al. and by us. [Chemical structures of ARI
and SDI used byCameron et al. (6), Obrosova et al. (34), and by
us are shown in OAS V.]
Failure of the ARI zopolrestat to reverse MNCV deficits
after 2 weeks of treatment in our studies is likely attributable
to its lower in vivo potency versus the ARI WAY-121,509 used
by Cameron et al. Consistent with this notion, sciatic nerve
fructose levels in WAY-121,509–treated diabetics were
markedly reduced to only 16% of fructose levels in nondia-
betic controls; in contrast, fructose levels in zopolrestat-
treated diabetics were 76% of fructose levels in nondiabetic
controls. The suggestion by Cameron et al. (6) that MNCV
deficits in untreated diabetics are attributable to decreased
blood flow (i.e., ischemia), even in diabetes of short duration
(6, 7), is discordant with the current observations andwith the
findings of Chang et al. (10), Ido et al. (21), and others ad-
dressed in OAS II-A.
Treatment of diabetic rats with SDI-157 (also named
S-0773) in an earlier study by Obrosova et al (34) failed to
prevent increases in neural NADH=NADþc. That finding
differs from observations in the current experiments in which
treatment with CP-166,572 (also named SDI-158) normalized
sciatic nerve NADH=NADþc (Fig. 1, Table 1) and was as ef-
ficacious as ARI in preventing MNCV deficits in all three
experiments in which MNCV was assessed (Figs. 1 and 2;
Table 4). (Chemical structures of SDIs shown in OAS V.)
SDI-157 is a prodrug that is activated in vivo in the liver to
the active chemical species SDI-158 (13). SDI-157 was ad-
ministered at a dose of 100mg=kg bwt=day, whereas the
SDI-158 (CP-166,572) was administered at a twofold higher
dose of 200mg=kg bwt=day. Because the half-life of SDI-157
and SDI-158 in serum and nerve of rats is very short (31-page
359), i.e., < 30min, the duration of its pharmacologic effect is
expected to be highly sensitive to the plasma level achieved.
Moreover, the efficacy of SDI also is likely to be sensitive to
variability in tissue drug levels because SDH blockade
markedly elevates nerve levels of sorbitol substrate for SDH
(e.g., about four- to fivefold vs. untreated diabetics (Tables
1,2, and 4); as SDH blockade wanes, rates of sorbitol oxida-
tion can exceed rates in untreated diabetics (45).
The 44% higher coefficient of variation of NADH=NADþc
ratios in SDI-treated diabetics versus ARI-treated diabetics
(Table 3) suggests that inhibitory levels of the short-half-life
SDI were not maintained in some of the animals in this group,
despite the high dose of SDI administered (200mg=kg
bwt=day) and the water-dosing paradigm. This probability
is consistent with evidence that a very high degree of SDH
inhibition (i.e., >91% normalization of nerve fructose lev-
els) must be achieved to demonstrate SDI efficacy, as
Table 5. Effects of Diabetes, SDI, and ARI on Sciatic Nerve: Lactate and Pyruvate Levels,
and Lactate=Pyruvate (L=P) Ratios in Rats with Diabetes of 5-, 10- (Reversal Study 1), and 18-Weeks Duration,
and Malate and Malate=Pyruvate (M=P) Ratios in Rats with Diabetes of 18-Weeks Duration
5wk 10wk 18wk
Lactate Pyruvate Lactate Pyruvate Lactate Pyruvate Malate M=P
Controls 3.52þ 1.19 0.32þ 0.08 2.03 0.68 0.16 0.04 4.90 1.78 0.23þ 0.07 0.50 0.07 2.41 1.25
L=P 11.56 4.32 12.70 4.39 23.41 7.13
Diabetics 6.36 2.37{ 0.36 0.13 3.13 0.89{ 0.13 0.041 4.93 1.39 0.13þ 0.05§ 0.49 0.11 4.32 1.97*
L=P 18.17 4.41* 26.13 8.16* 46.03 17.87*
DþSDI 5.88 2.93§ 0.48 0.20§2 2.76 0.88§ 0.15 0.06 5.01 1.50 0.23 009b 0.56 0.08 2.71 1.17b
L=P 12.43 319b 22.77 12.94§ 27.21 11.48b
DþARI 5.28 2.06a 0.46 0.16§2 3.87 l.57§ 0.20 0.05a3 3.95 0.96 0.16 0.06c 0.49 0.12 3.44 1.94
L=P 11.61 3.24a 16.13 655b 27.70 8.69a
Data are expressed as mean SD for lactate and pyruvate levels and mean L=P ratios for animals in each group. Numbers of animals for
each duration of diabetes are shown in corresponding Tables 1 and 2 and Fig. 1.
Lactate, pyruvate, and malate levels are expressed as nmol=mg DNA.
Different from Controls: *p< 0.001, {p 0.005, §p< 0.03, 1p¼ 0.05-0.1.
Different from Diabetics: ap< 0.004, bp< 0.01, cp< 0.05, 2p¼ 0.05–0.1.
Different from Diabeticsþ SDI: 3p¼ 0.02.
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demonstrated for ARI (6). Thus, we hypothesize that the
failure of SDI to normalize neural NADH=NADþc in the ear-
lier experiment (34) may be explained by the combined effects
of (a) the 50% lower dose administered of the prodrug SDI-157
versus the active drug SDI-158 in the present experiments, (b)
the rapid build-up of sorbitol substrate for SDH caused by the
SDI, and (c) the very short half-life of the active SDI.
Therefore, the suggestion that hypoxia-like metabolic
changes [i.e., increases in NADH=NADþc, in tissues of dia-
betic rats (55)] are sequelae of increased AR activity, inde-
pendent of increased sorbitol oxidation (36) remains
discordant with the present observations, as well as with
previous findings demonstrating that exposure of normoxic
normoglycemic cells and tissues to elevated sorbitol levels
in vivo and in vitro evokes metabolic imbalances or vascular
dysfunction or both, like those evoked by hyperglycemia (9,
12, 26, pages 9–10 in OAS IV-A of 30, 46, 47, 49, 53).
Likewise, the suggestion (4) that the increase in free
NADH=NADþc evoked by diabetes is attributable to a
marked decrease in total NADþt because of its consumption
by poly(ADP-ribose) polymerase (PARP) is inconsistent with
(a) increased levels of total NADHt with no change in NADt
(NADHt plus NADþt) (14) and increased levels of NADHt
and NADþt (18) in retinas of diabetic rats, (b) the insignificant
decrease in free NADþc associated with a twofold increase in
NADH=NADþc discussed later, (c) the demonstration that
hyperglycemia increases free NADH=NADþc¼ lactate=
pyruvateKLDH ratios in human erythrocytes (48) that lack
nuclei and mitochondria, and (d) observations of other
investigators addressed in OAS II-E. Interestingly, recent
observations suggest that activated PARP may further con-
tribute to oxidative–nitrosative stress (OAS II-E, 9).
The second conclusion (see earlier; i.e., the primacy of in-
creased NADH=NADþc vs. increased NADH=NADþm in
mediating diabetes-induced neural and vascular dysfunction)
is supported by observations that (a) SDH and AR are known
to be primarily cytoplasmic enzymes (31), and (b) inhibition of
either enzyme normalized=attenuated increased sciatic nerve
free NADH=NADþc (Fig. 1; Table 1), impairedMNCV (Figs. 1
and 2; Table 4), and vascular dysfunction (Table 1), while
having little or no impact on associated increases in free
NADH=NADþm (Fig. 1; Table 3). Whatever putative mito-
chondrial changes may have contributed to neural and vas-
cular changes, independent of the increase in NADH=
NADþm, the observations that ARI and SDI prevented vas-
cular and neural dysfunction indicates that those putative
changes also were prevented. The most likely explanation for
the increases in NADH=NADþm in these experiments is in-
creased oxidation of fatty acids and=or ketones that were
significantly increased in Reversal Study 1 (Table 3) and in the
18-week study (see Results) and were not attenuated by ARI
or SDI.
Limitations of the current studies are that they do not di-
rectly address (a) potentially important increased superoxide
production caused by hypoxic=ischemic vascular disease in
chronic diabetes (OAS I-C2) or (b) mitochondrial superoxide
production. The effects of the two types of inhibitors of cy-
toplasmic enzymes (AR and SDH) in the present studies do
not exclude potentially important downstream enzymatic
reactions=sequelae in the same or other cellular compart-
ments. A positive control to normalize NADH=NADþm, but
not NADH=NADþc, would be of interest for future studies.
The possible relationship between increased mitochondrial
leakage, i.e., opening of MPTPs (1) and changes in NADH=
NADþm] also need further study. Because the effects of dia-
betes on NADH=NADþc and NADH=NADþm are complex
and their roles in initiating complications of diabetes remain
controversial (4–8, 10, 11, 21, 29, 34, 36, 56), they are discussed
critically inmore detail in the current OAS II and in theOAS in
(30) for interested readers. Notably, observations and specu-
lations thought to be inconsistent with the importance of
sorbitol oxidation do not withstand scrutiny.
An additional limitation of the current studies is the ques-
tion of the absolute specificity of the inhibitors used. Off-
target effects are always possible for low-molecular-weight
inhibitors. This is the reason that two structurally distinct
inhibitors of ARwere used (i.e., sorbinil and zopolrestat). That
similar results were obtained with either ARI attests to the
salutary effects being a result of inhibition of the intended
target, AR. The result is further supported and refined by
using the SDI, an inhibitor in the second step of the pathway.
However, only one structural class of SDIs is active in vivo, the
one used. SDI normalized impaired nerve conduction in di-
abetic rats, but paradoxically evoked ultrastructural changes
in autonomic nerves (iliac mesenteric nerves) and in pre-
vertebral sympathetic superior mesenteric ganglia in the same
animals (OAS V-A in ref.30). The functional significance and
mechanism of those ultrastructural changes remains unclear.
The fundamental issue raised by the current observations is
the basic mechanism by which NADHc generated by oxida-
tion of sorbitol causes (a)metabolic imbalances and associated
neural and vascular dysfunction observed in early diabetes,
and (b) late complications of diabetes that are now generally
agreed to be linked to excess production of ROS (4, 5, 20, 29,
53). Equations 1 and 2 (see Methods) are the keys to under-
standing this mechanism and the pathophysiologic impor-
tance of sorbitol oxidation in generating relatively smallmolar
increases in free NADHc, uncoupled from subsequent down-
stream production of equimolar pyruvate.
As shown in Eq. 2, free NADH=NADþc¼ (lactate=pyruvate)
KLDH (KLDH¼ 1.11104 at pH¼ 7.0; i.e.,*1=10,000). Molar
lactate=pyruvate ratios in a wide spectrum of normal cells and
tissues range from *10=1 to 20=1 [e.g., liver (54) and nerve
(Table 5)]. Therefore, based on Eq. 2, a lactate=pyruvate ratio of
10:1 corresponds to a free NADH=NADþc ratio of*10=10,000
or*1=1000 or*0.001 (i.e.,*1mole ofNADHcper 1,000moles
of NADþc). In light of this large difference in concentrations of
NADHc and NADþc, molar changes in NADHc have a far
greater impact on NADH=NADþc and lactate=pyruvate ratios
than do equimolar changes in pyruvate, lactate, or NADþc, in
decreasing order of impact. For example, accumulation of just 1
additional mole of NADHc per 1,000 moles of NADþc will
increase NADHc levels by about twofold (from 1 to 2 moles of
NADHc per 1,000moles of NADþc). This will bemanifested by
a corresponding approximately twofold increase in NADH=
NADþc, from*0.001 to*0.002, and in lactate=pyruvate ratios
from*10 to*20, as observed (a) in the current studies in the
5-week experiment (Tables 1 and 5), the 10-week Reversal
Study 1 (Tables 3 and 5), and the 18-week experiment (Fig. 1;
Table 5); (b) in previous reports in retina, sciatic nerve, and
liver of diabetic animals (17, 34–37, 41, 54), and (c) normal rat
retinas and sciatic nerve endoneuria incubated in 30 versus
5mM glucose that are prevented by ARI (30, and current
OAS IV).
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If the 1 additional mole of NADHc per 1,000 moles of
NADþc were generated by reduction of 1 mole of NADþc to
NADHc via oxidation of sorbitol, then SDI or ARI should
prevent the increase in NADH=NADþc, as observed in these
experiments (Fig.1; Table 1, and by the ARI in Table 3). In
contrast, if the increases in NADH=NADþc were due to in-
creased NADHc formation independent of sorbitol oxidation
(e.g., by hypoxia), ARI and SDIwould not be expected to affect
it. This prediction has been tested by Nyengaard et al. (30) on
the additive effects of hyperglycemia and hypoxia on free
NADH=NADþc (manifested by increases in lactate=pyruvate
ratios) in incubated normal rat retinas and sciatic nerve
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endoneuria (OAS IV). Hyperglycemia and hypoxia additively
increased lactate=pyruvate ratios, triose phosphates, and
G3P; the increases evoked by hyperglycemia were prevented
by ARI, which did not affect the associated increases evoked
by hypoxia.
The evidence that accumulation of just 1 mole of free
NADHc per 1,000 moles of free NADþc doubles the concen-
tration of free neural NADHc and is associatedwith increased
neural blood flow suggests that (a) the level of free NADHc is
an exquisitely sensitive sensor of blood flow need due to
‘‘hyperglycemic pseudohypoxia’’ (55), as well as true hypoxia,
manifested by increases in NADH=NADþc; and (b) increased
levels of NADHc fuel signaling pathways that augment blood
flow, (e.g., Table 1) (22, 23, 27, 51). This interpretation is con-
sistent with observations (46) that exposure of granulation
tissue to elevated levels of sorbitol (at normal glucose levels)
or hyperglycemia increased blood flow and VAP (identical to
those in nerve and retina in Table 1) that were prevented by
SDI, SOD, or VEGF antibodies.
The near-equilibrium between free NADH=NADþc and
lactate=pyruvate ratios maintained by LDH also plays a piv-
otal role in modulating energy metabolism, blood flow, and
superoxide production in a spectrum of physiologic and
pathologic conditions, including hypoxia and increased
physiologic work in humans and animals addressed in OAS I-
C. Thus, infusion of lactate (which produces ‘‘prooxidant’’
NADHc when oxidized by LDH) (a) increases blood flow in
sciatic nerve, retina, and other tissues in normal rats that are
prevented by co-infusion of ‘‘antioxidant’’ pyruvate (23); and
(b) augments the already increased blood flows evoked by
increased physiologic work in normal humans and animals
that also are prevented by co-infusion of pyruvate (22, 23, 27,
51, and OAS 1-C).
Observations in the 18-week study that diabetes increased
sciatic nerve NADPH=NADPþc (Table 2) and NADH=
NADþc by *1.8-fold (Fig. 1), both of which were prevented
by the SDI, are consistent with corresponding observations in
an earlier report that were prevented by an ARI (35). Al-
though the explanation for the increase in NADPH=
NADPþc is not entirely clear, evidence that increased levels of
NADHc generated by oxidation of sorbitol fuel superoxide
production (46) and diacylglycerol synthesis (57) suggests
that increased levels of NADHc might also fuel reduction of
oxidized NADPþc to NADPHc via the pyruvate=malate cycle
(42), discussed in OAS I-B. This possibility is consistent with
evidence that 40% of the NADPHþHþ used for fatty acid
synthesis from glucose is provided by the pyruvate=malate
cycle. These observations suggest that increased NADHc
generated by oxidation of sorbitol may augment superoxide
production by three mechanisms: (a) as substrate for NADH-
driven oxidases, (b) as substrate for the pyruvate=malate cycle
to increase NADPHc as fuel for NADPH-driven oxidases, and
(c) by fueling DAG synthesis, which activates the PKC that
activates some isoforms of NADPH oxidase (Fig. 3). The third
mechanism is supported by observations (57) that exposure of
skin-chamber granulation tissue vessels to elevated glucose
levels in nondiabetic rats (circumventing other metabolic and
hormonal imbalances associated with the diabetic milieu)
increased DAG levels and VAP, both of which were pre-
vented by addition of pyruvate (which compensates for the
uncoupling of pyruvate production when NADHc is pro-
duced by sorbitol oxidation rather than by glycolysis).
Taken together, observations in these experiments support
an important role for increased ‘‘prooxidant’’ NADHc gener-
ated by sorbitol oxidation in fueling superoxide production,
metabolic imbalances, and neural and vascular dysfunction
evoked by hyperglycemia. Uncoupling of prooxidant
NADHc formed by sorbitol oxidation from equimolar for-
mation of ‘‘antioxidant’’ pyruvate constrains reoxidation of
NADHc to NADþc by LDH coupled to the reduction of py-
FIG. 3 NADHc generated by sorbitol oxidation is reoxidized to NADþc largely by enzymes that promote the devel-
opment of diabetic complications. (A) Under steady-state normoglycemic conditions, glucose is metabolized via glycolysis to
synthesize ATP [in the cytoplasm via substrate phosphorylation (SP) and in mitochondria via oxidative phosphorylation (OP)]
only after electrons and protons are transferred fromGA3P to oxidizedNADþc (byGA3P-DH), reducing it toNADHc followed
by downstream formation of pyruvate equimolar to NADHc. Electrons and protons carried by NADHc can be transferred into
mitochondria via the malate-aspartate (Mal-Asp) and glycerol phosphate (G3P) electron shuttles (‚); pyruvate can be trans-
ferred intomitochondria via amitochondrial pyruvate carrier. All cells generate NADHc and pyruvate via glycolysis faster than
they are used for ATP synthesis in mitochondria. Excess NADHc is reoxidized to NADþc largely by lactate dehydrogenase
(LDH), coupled to reduction of excess pyruvate to lactate (¶) that diffuses out of the cell (e.g., for retina: 30, 50; for nerve: OAS
IV). Much smaller amounts of glucose are metabolized by the sorbitol pathway through which sorbitol dehydrogenase (SDH)
catalyzes oxidation of sorbitol to fructose coupled to reduction of equimolar NADþc to NADHc. However, SDH does not
generate pyruvate required for reoxidation of NADHc to NADþc by LDH. This NADHc is reoxidized to NADþc largely
via alternative pathways (•): (1) NADH-driven oxidases that generate basal levels of superoxide (O2
) and (2) glycerol
3-phosphate-DH (G3P-DHc), which fuels synthesis of basal levels of diacylglycerol (DAG) and protein kinase C (PKC) activity.
Both of these mechanisms of reoxidation of NADHc to NADþc maintain normal steady-state ratios of NADH=NADþc¼
(lactate=pyruvate) KLDH (Eq. 2 in Methods). (B) Hyperglycemia augments glucose metabolism via glycolysis and via the
sorbitol pathway. In normal rat retina and sciatic nerve endoneuria incubated in 30 vs. 5mM glucose, glycolysis was increased
*1.5 fold [manifested by increased lactate production] (30, 50, current OAS-IV). Oxidation of sorbitol in the same endoneuria
(manifested by production of fructose equimolar to NADHc) was increased*11-fold. Because oxidation of sorbitol does not
form pyruvate, NADHc levels increase by 1.5- to twofold (manifested by increased ratios of NADH=NADþc in Fig. 1, Tables 1
and 3; refs.17, 34–37, 41), andmuchmore NADHc is reoxidized to NADþc via alternative pathways (•) (i.e., by NADHc-driven
oxidases that increase superoxide production and by G3P-DHc, which increases synthesis of diacylglycerol (DAG), activation
of protein kinase C (PKC), and activation of NADPH-driven oxidases to augment superoxide production further. The 1.5- to
twofold increases in NADHc also may contribute to product inhibition of GA3P-DH, which increases levels of GA3P and
DHAP (i.e., triose phosphates-TP (30, 48, 50, OAS IV) that are in equilibrium. Nonenzymatic degradation of TP (primarily
DHAP) forms methylglyoxal (MG), a potent nonenzymatic glycation agent. (For interpretation of the references to color in this
figure legend, the reader is referred to the web version of this article at www.liebertonline.com=ars).
‰
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ruvate to lactate that diffuses out of cells (Fig. 3). Thus,
NADHc levels increase (*1.5- to twofold) until their mass-
action effect drives reoxidation of NADHc to NADþc by (a)
NADH-driven oxidases that produce superoxide, and (b)
G3P-DHc that promotes de novo synthesis of DAG and acti-
vation of PKC (Fig. 3) that activates some isoforms of
NADPH-driven oxidases.
Observations that ARI and SDI increased sciatic nerve
pyruvate levels that were statistically significant or ap-
proached significance in five of six interventions (Table 5)
were associatedwith (a) normalization ofMNCV deficits, and
(b) normalization=attenuation of associated increases in
NADH=NADþc and vascular dysfunction that are consistent
with well-known antioxidant effects of pyruvate (OAS I).
Pyruvate (a) stoichiometrically degrades H2O2 coupled to its
own nonenzymatic oxidative decarboxylation, and (b) pre-
vents superoxide production by NADH-driven oxidases by
driving reoxidation of ‘‘prooxidant’’ NADHc to NADþc by
LDH, coupled to reduction of ‘‘antioxidant’’ pyruvate to lac-
tate that diffuses out of cells (Fig. 3).
We suggest that the second mechanism may be especially
important, because it also will attenuate product inhibition of
GA3P-DH (by increased levels of NADHc) and associated
metabolic imbalances (i.e., increased triose phosphate levels
that (a) fuel synthesis of DAG that activates PKC that activates
some isoforms of NADPH-driven oxidases, etc. (30-OAS III
p. 7, 57, and current OAS I); and (b) undergo concentration-
dependent degradation to methylglyoxal, a toxic and potent
glycating agent (Fig. 3). GA3P-DH activity also can be in-
hibited by oxidative damage caused by superoxide; the pres-
ent observations support the importance of increased sorbitol
oxidation as the primary source of superoxide rather than
increased mitochondrial oxidation of pyruvate (4, 5, 29).
Although we conclude that our current observations (to-
gether with evidence published by other investigators) are
consistent with a key role for increased sorbitol oxidation in
mediating diabetic complications, it is important that we also
identify credible alternative interpretations of observations
and caveats to various speculations in the literature. For in-
terested readers, these are discussed in detail in OAS II.
Therapeutic implications of these experiments include the
need to minimize metabolism of glucose via the sorbitol
pathway by (a) maintaining glucose levels as close to normal
as feasible, and (b) developing more-potent ARIs to prevent
sorbitol oxidation and associated production of superoxide
and metabolic imbalances that mediate complications of di-
abetes (31, 32). Recent observations in animal models of dia-
betes suggest that the disappointing efficacy of ARIs in
normalizing neural and vascular dysfunction in past clinical
trials may be largely attributable to inadequate inhibition of
the sorbitol pathway (31, 32). Pyruvate supplementation in
some form also merits further exploration in view of its ex-
traordinary antioxidant effects in animal models of diabetes
and hypoxic injury (OAS I-C).
Conclusions
Observations in these experiments support the importance
of increased ‘‘prooxidant’’ NADHc generated by sorbitol ox-
idation in fueling superoxide production and associated
metabolic imbalances, impaired nerve conduction, and vas-
cular dysfunction evoked by hyperglycemia. Uncoupling of
‘‘prooxidant’’ NADHc formed by sorbitol oxidation from
equimolar formation of ‘‘antioxidant’’ pyruvate constrains re-
oxidation of NADHc to NADþc by LDH, which is coupled to
the reduction of pyruvate to lactate that diffuses out of cells
(Fig. 3). IncreasingNADHc levels drive reoxidation ofNADHc
to NADþc by (a) NADH-driven oxidases that produce su-
peroxide, and (b) G3P-DHc, which promotes synthesis of
DAG, activation of PKC, and activation of NADPH-driven
oxidases that further augment superoxide production (Fig. 3).
Attenuation of diabetes-induced vascular and neural dys-
function by ARI, SDI, and pyruvate supplementation is ex-
plained by (a) prevention of sorbitol formation by ARI, (b)
inhibition of sorbitol oxidation by SDI, and (c) reoxidation of
excess NADHc to NADþc coupled to reduction of pyruvate to
lactate by LDH rather than NADH- and NADPH-driven ox-
idases and G3P-DHc.
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ARI¼ aldose reductase inhibitor
BREC¼ bovine retinal endothelial cell
DAG¼diacylglycerol
DHAP¼dihydroxyacetone phosphate (a triose
phosphate-TP











HUVEC¼human umbilical cord endothelial cell
LDH¼ lactate dehydrogenase
L=P¼ lactate=pyruvate ratio
MABP¼mean arterial blood pressure
MDA¼malondialdehyde
MG¼methylglyoxal
MNCV¼motor nerve conduction velocity









ROS¼ reactive oxygen species
SDH¼ sorbitol dehydrogenase
SDI¼ sorbitol dehydrogenase inhibitor
SIRT1¼ silent information regulator 2




TCA¼ tricarboxylic acid cycle (Krebs cycle, citric acid
cycle)
TP¼ triose phosphate
VEGF¼vascular endothelial growth factor
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